Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H ( (HK:2291) ) has provided an announcement.
Lepu ScienTech Medical Technology reported audited results for 2025 showing revenue rising 11.9% year on year to RMB527.9 million and gross profit up 5.4% to RMB447.0 million, supported by its portfolio of interventional cardiac devices. Research and development spend was broadly flat at RMB58.1 million, while net profit attributable to shareholders slipped 2.4% to RMB239.7 million, indicating some margin pressure despite top-line growth.
The board recommended a lower final dividend of RMB0.5 per share versus RMB0.62 a year earlier, signaling a more cautious capital return stance even as the company maintains investment in innovation. With multiple products on the market and a sizable pipeline under registration and development, the results underscore Lepu ScienTech’s ambition to consolidate its leadership in China’s interventional medical device sector while balancing profitability, shareholder payouts and continued R&D.
More about LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H
Lepu ScienTech Medical Technology (Shanghai) Co., Ltd. is a China-based interventional cardiovascular device maker focused on heart disease treatments. With over 20 years of experience in traditional metal devices, it has expanded into degradable implants and frontier areas such as heart valves, cardiac mechanical circulatory support and atrial septal puncture solutions. The company markets 32 occluders, heart valves and accessory products and is advancing additional candidates through registration and R&D.
Average Trading Volume: 420,162
Technical Sentiment Signal: Sell
Current Market Cap: HK$5.5B
For a thorough assessment of 2291 stock, go to TipRanks’ Stock Analysis page.